Your browser is no longer supported. Please, upgrade your browser.
Settings
SNDX Syndax Pharmaceuticals, Inc. daily Stock Chart
SNDX [NASD]
Syndax Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.66 Insider Own0.10% Shs Outstand26.93M Perf Week1.58%
Market Cap207.63M Forward P/E- EPS next Y-2.17 Insider Trans- Shs Float26.93M Perf Month2.39%
Income-68.90M PEG- EPS next Q-0.45 Inst Own72.30% Short Float2.40% Perf Quarter50.59%
Sales1.50M P/S138.42 EPS this Y-0.70% Inst Trans8.27% Short Ratio3.52 Perf Half Y57.67%
Book/sh2.54 P/B3.04 EPS next Y-6.40% ROA-71.50% Target Price18.75 Perf Year-6.77%
Cash/sh3.54 P/C2.18 EPS next 5Y- ROE-107.50% 52W Range3.39 - 9.15 Perf YTD73.26%
Dividend- P/FCF- EPS past 5Y3.50% ROI-143.20% 52W High-6.56% Beta-
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low152.21% ATR0.48
Employees38 Current Ratio6.20 Sales Q/Q0.00% Oper. Margin- RSI (14)65.30 Volatility6.48% 6.45%
OptionableYes Debt/Eq0.00 EPS Q/Q33.20% Profit Margin- Rel Volume2.41 Prev Close7.71
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume183.35K Price8.55
Recom1.80 SMA2013.63% SMA5020.10% SMA20039.06% Volume229,874 Change10.89%
Mar-08-19Reiterated H.C. Wainwright Buy $22 → $16
Jan-04-19Initiated Robert W. Baird Outperform
Jan-05-18Initiated B. Riley FBR, Inc. Buy $40
Mar-16-17Initiated FBR & Co. Outperform $27
Mar-02-17Initiated Instinet Buy $27
Oct-07-16Initiated Guggenheim Buy
Mar-28-16Initiated Morgan Stanley Overweight $22
Mar-28-16Initiated JMP Securities Mkt Outperform $28
Mar-28-16Initiated Citigroup Buy $24
Jun-13-19 07:00AM  Syndax to Present at the JMP Securities Life Sciences Conference PR Newswire
Jun-08-19 08:28PM  Edited Transcript of SNDX earnings conference call or presentation 6-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-30-19 05:33AM  5 Stellar Stocks For Under $10 TipRanks
May-28-19 11:18AM  Sirnaomics Appoints Allan L. Shaw as Chief Financial Officer PR Newswire
May-16-19 10:45AM  Have Insiders Been Buying Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares This Year? Simply Wall St.
May-14-19 07:00AM  Syndax to Present at the UBS Global Healthcare Conference PR Newswire
May-06-19 06:05PM  Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:53PM  Syndax: 1Q Earnings Snapshot Associated Press
04:05PM  Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update PR Newswire
Apr-29-19 07:00AM  Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019 PR Newswire
Apr-01-19 10:33AM  Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting PR Newswire -6.67%
Mar-27-19 07:00AM  Syndax Announces $26.2 Million Offering of Common Stock and Warrants PR Newswire +16.09%
Mar-13-19 03:45AM  Edited Transcript of SNDX earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents -5.42%
Mar-12-19 01:35PM  What Do Analysts Think About Syndax Pharmaceuticals, Inc.s (NASDAQ:SNDX) Earnings Trend? Simply Wall St. +5.73%
Mar-07-19 04:05PM  Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update PR Newswire
Mar-06-19 07:00AM  Syndax to Present at the Cowen 39th Annual Health Care Conference PR Newswire -8.92%
Feb-28-19 07:00AM  Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019 PR Newswire
Feb-27-19 04:47PM  Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019 PR Newswire
Feb-25-19 10:30AM  Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
Feb-12-19 07:55AM  New Research: Key Drivers of Growth for Cronos Group, Spectrum Brands, Black Hills, Entercom Communications, CSS Industries, and Syndax Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-07-19 07:00AM  Syndax Highlights 2019 Clinical and Corporate Outlook PR Newswire +14.17%
Jan-04-19 12:23PM  Can We See Significant Institutional Ownership On The Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Share Register? Simply Wall St. +15.96%
Dec-04-18 12:17AM  Edited Transcript of SNDX earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -9.36%
Dec-03-18 10:00AM  Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting PR Newswire +6.86%
Nov-12-18 08:50AM  Investor Expectations to Drive Momentum within CommScope Holding, AMC Networks, Henry Schein, Lindblad Expeditions, Apple Hospitality REIT, and Syndax Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Nov-05-18 06:30PM  Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates Zacks -5.08%
04:05PM  Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update PR Newswire
Nov-01-18 04:05PM  Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting PR Newswire
Oct-29-18 07:00AM  Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018 PR Newswire -7.98%
Oct-26-18 08:17AM  The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default Benzinga -17.05%
Oct-25-18 04:05PM  Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer PR Newswire
Oct-18-18 08:35AM  Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants, Aerohive Networks, KalVista Pharmaceuticals, and Adtalem Global Education New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Sep-26-18 07:00AM  Syndax to Present at the 2018 Cantor Global Healthcare Conference PR Newswire
Sep-25-18 04:05PM  Syndax Announces Changes to its Board of Directors PR Newswire
08:51AM  Do Options Traders Know Something About Syndax (SNDX) Stock We Don't? Zacks
08:30AM  The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering Benzinga
Sep-24-18 04:05PM  Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer PR Newswire +6.79%
Sep-12-18 03:54PM  Are Syndax Pharmaceuticals Incs (NASDAQ:SNDX) Interest Costs Too High? Simply Wall St. -9.79%
Sep-11-18 12:27PM  Edited Transcript of SNDX earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Sep-05-18 05:00PM  Syndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer PR Newswire
Aug-28-18 07:00AM  Syndax Announces Participation at Three Upcoming Investor Conferences PR Newswire
Aug-27-18 08:15AM  New Research: Key Drivers of Growth for REGENXBIO, Syndax Pharmaceuticals, Rowan Companies, CTS, Basic Energy Services, and Impinj Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-07-18 06:20PM  Syndax Pharmaceuticals (SNDX) Reports Q2 Loss Zacks
05:15PM  Syndax: 2Q Earnings Snapshot Associated Press
04:05PM  Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update PR Newswire
02:30PM  Syndax Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Jul-31-18 07:00AM  Syndax to Announce Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018 PR Newswire
Jun-22-18 07:35AM  Research Report Identifies NetScout, Waterstone Financial, Lindblad Expeditions, Syndax Pharmaceuticals, Hospitality Properties Trust, and NewMarket with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
May-30-18 04:05PM  Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration PR Newswire
07:00AM  Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences PR Newswire
May-21-18 07:30AM  Blog Exposure - Syndax Pharma Shares Results of Phase-2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA ACCESSWIRE
May-17-18 07:00AM  Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) PR Newswire -22.57%
May-16-18 08:02AM  Edited Transcript of SNDX earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-08-18 06:16PM  Syndax: 1Q Earnings Snapshot Associated Press
04:05PM  Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update PR Newswire
May-03-18 07:40AM  Detailed Research: Economic Perspectives on Park-Ohio, WageWorks, Parker-Hannifin, Sturm, Ruger, Syndax Pharmaceuticals, and Fastenal What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-01-18 07:00AM  Syndax to Announce First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 8, 2018 PR Newswire
Apr-25-18 04:05PM  Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting PR Newswire
Apr-13-18 07:00AM  Syndax to Present at the 2018 American Association for Cancer Research Annual Meeting PR Newswire
Mar-19-18 08:00AM  Analysis: Positioning to Benefit within ICF International, Invitae, Encore Wire, Alexandria Real Estate Equities, Syndax Pharmaceuticals, and Vical Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-17-18 08:32AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Mar-15-18 08:10AM  Todays Research Reports on Trending Tickers: CRISPR Therapeutics and Syndax Pharmaceuticals ACCESSWIRE -8.10%
Mar-14-18 03:43PM  Here's Why Syndax Pharmaceuticals Is Soaring Today Motley Fool +28.36%
Mar-06-18 06:26PM  Edited Transcript of SNDX earnings conference call or presentation 5-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-05-18 04:37PM  Syndax reports 4Q loss Associated Press
04:05PM  Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update PR Newswire
12:00PM  Syndax Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
07:00AM  Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences PR Newswire
06:19AM  Syndax Pharmaceuticals Inc (NASDAQ:SNDX): Does The -16.61% Earnings Decline Make It An Underperformer? Simply Wall St.
Feb-26-18 07:00AM  Syndax to Announce Fourth Quarter and Year-end 2017 Financial Results and Host Conference Call and Webcast on March 5, 2018 PR Newswire
Feb-22-18 07:00AM  Syndax Announces Presentations at the 2018 American Association for Cancer Research Annual Meeting PR Newswire
Feb-01-18 07:00AM  Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca PR Newswire
Jan-18-18 09:45AM  4 of the Best Stocks to Buy on Earnings Acceleration InvestorPlace
09:25AM  3 Top-Ranked Drug Stocks That Are Broker Favorites InvestorPlace
09:20AM  Zacks.com highlights: Dollar Tree, Syndax Pharmaceuticals, Financial Partners and Union Bankshares Zacks
Jan-16-18 08:41AM  Can Syndax (SNDX) Keep the Earnings Streak Alive This Quarter? Zacks
Jan-10-18 07:00AM  Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer PR Newswire
Jan-09-18 08:30AM  Investor Expectations to Drive Momentum within Cutera, Matrix Service, PRA Group, Materion, Second Sight Medical Products, and Syndax Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire +5.35%
Dec-28-17 12:41PM  ETFs with exposure to Syndax Pharmaceuticals, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:37AM  Syndax Pharmaceuticals, Inc. :SNDX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-13-17 01:58PM  ETFs with exposure to Syndax Pharmaceuticals, Inc. : December 13, 2017 Capital Cube
Nov-13-17 02:42PM  Edited Transcript of SNDX earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents -15.92%
Nov-11-17 03:00PM  Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting PR Newswire
Nov-07-17 06:24PM  Syndax reports 3Q loss Associated Press
04:05PM  Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update PR Newswire
12:10PM  Syndax Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
08:00AM  Syndax to Present at the SITC 32nd Annual Scientific Meeting PR Newswire
Oct-31-17 07:00AM  Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017 PR Newswire
Oct-19-17 07:10AM  Featured Company News - Syndax Pharma Signs Worldwide License Agreement for Allergan's Portfolio of Menin-MLL Inhibitors ACCESSWIRE
Oct-17-17 07:01AM  Syndax Announces $25 Million Registered Direct Offering of Common Stock PR Newswire
07:00AM  Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors PR Newswire
Oct-05-17 07:00AM  Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin PR Newswire
Sep-20-17 07:00AM  Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-12-17 06:02AM  The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals Zacks -6.63%
Aug-30-17 07:00AM  Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences PR Newswire
Aug-24-17 10:49AM  Syndax Pharmaceuticals, Inc. :SNDX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube +5.94%
Aug-14-17 02:25PM  Edited Transcript of SNDX earnings conference call or presentation 10-Aug-17 8:30pm GMT Thomson Reuters StreetEvents +9.17%
Aug-10-17 09:43PM  Syndax reports 2Q loss Associated Press
04:05PM  Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update PR Newswire
01:00PM  Investor Network: Syndax Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; with Tecentriq (atezolizumab) in a Phase Ib/II clinical trials to treat patients with triple-negative breast cancer, and HR+ and HER2- metastatic breast cancer; and with Bavencio (avelumab) in a Phase Ib/II clinical trials for the treatment of ovarian cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I dose escalation trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is in Phase I/Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; Merck KGaA and Pfizer; and AstraZeneca plc. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.